QNCX: Quince Therapeutics Inc Company Short-Term Debt

Symbol and logo of brand Quince (QNCX)

Quince Therapeutics focuses on developing therapies for orphan diseases through innovative cellular delivery. The level of short-term debt load demonstrates the issuer's financial discipline, with the current metric standing at 0.00. High scalability is ensured by drug patents, while a unique erythrocyte encapsulation method minimizes market pressure, shifting the competition toward scientific efficacy.

QNCX (quincetx.com) Company Short-Term Debts history from 04/28/2023 to 10/12/2026

QNCX (Quince Therapeutics Inc): analytical breakdowns and indicator data

- current quotes and average value forecast:
Price Chart Quince|QNCX - Fair Value Consensus
- market capitalization information:
Market Value Quince Therapeutics, Inc.|QNCX - Real Price to Acquire Entire Company
- shareholders' equity book value data:
Book Value per Share Quince Therapeutics|QNCX - Book Capitalization|Market Cap to Net Assets Ratio quincetx.com|QNCX - Aggregate Asset Value
- debt and liquidity data:
Debt to Equity Quince Therapeutics|QNCX - Long-Term Debt to Equity Ratio|Short-Term Debt to Capital Quince|QNCX - Company Cumulative Debt|Debt to Book Value Quince Therapeutics, Inc.|QNCX - Amount of Long-Term Liabilities|Company Short-Term Debts Quince Therapeutics|Quick Ratio quincetx.com
- net income and valuation multiples indicators:
QNCX - Company Net Income
Basic company analysis:quincetx.com - QNCX
Mass-produced product of Quince Therapeutics Inc

By outsourcing research and maintaining a lean scientific staff, Quince Therapeutics (QNCX) minimizes operating expenses, which reduces the need for emergency borrowing. This snapshot of short-term debt measures the issuer's ability to service urgent obligations without liquidating assets, reflecting current resilience to liquidity shocks and changes in the tax regime, which is critical for assessing the solvency of a biotechnology business.

Who Quince Therapeutics competes with

ASND - Company Short-Term Debt|Company Short-Term Loans and Borrowings MDGL (Madrigal Pharmaceuticals Inc)|Corcept (CORT) - Company Short-Term Debt|Company Current Liabilities Rhythm Corp|AKRO (Akero Therapeutics) - Company Short-Term Debts|Company Short-Term Debts metsera.com|Company Current Liabilities MLTX (MoonLake)|CRNX (Crinetics Pharmaceuticals, Inc.) - Company Short-Term Loans and Borrowings|Company Short-Term Debt NewAmsterdam Pharma N.V. NAMS|SLNO - Company Current Liabilities|Amicus Therapeutics - Company Short-Term Debts|Short-Term Debt 89bio.com|AGIO (Agios Pharmaceuticals, Inc.) - Company Current Liabilities|GPCR: Amount of Current Liabilities|MDXG (MiMedx Group) - Company Short-Term Debts|Company Short-Term Debts Rezolute Bio|Company Short-Term Debts LXRX|Company Short-Term Debt MBX (mbxbio.com)|Company Short-Term Debt Altimmune ALT|Aardvark Therapeutics Inc. (AARD) - Short-Term Debt|SGMT - Company Short-Term Debt|BIOA: Company Short-Term Debt|BMEA: Company Short-Term Debts|GUTS - Short-Term Debt Volume|Company Short-Term Debt vTv Therapeutics, Inc.|Agape ATP Corp. (ATPC) - Short-Term Debt Volume|Company Short-Term Debt Pluri Inc. (PLUR)|Company Current Liabilities synlogictx.com SYBX|Company Short-Term Debt Lipocine Inc. LPCN|Short-Term Indebtedness Matinas BioPharma Holdings, Inc.|SPRB: Company Current Liabilities|GLTO - Company Short-Term Debts|CTCX: Company Short-Term Debts|LUMO - Short-Term Debt Volume|Company Short-Term Debt Organovo Holdings, Inc.|Company Short-Term Indebtedness RDUS (radiuspharm.com)